DOI QR코드

DOI QR Code

Elevated Circulating CD19+ Lymphocytes Predict Survival Advantage in Patients with Gastric Cancer

  • Yu, Qi-Ming (Zhejiang Cancer Research Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center) ;
  • Yu, Chuan-Ding (Zhejiang Cancer Research Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center) ;
  • Ling, Zhi-Qiang (Zhejiang Cancer Research Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center)
  • 발행 : 2012.05.30

초록

Background: Circulating lymphocyte subsets reflect the immunological status and might therefore be a prognostic indicator in cancer patients. Our aim was to evaluate the clinical significance of circulating lymphocyte subset in gastric cancer (GC) cases. Methods: A retrospective study on a prevalent cohort of 846 GC patients hospitalized at Hospital from Aug 2006 to Jul 2010 was conducted. We calculated the patient's disease free survival (DFS) after first hospital admission, and hazard ratios (HR) from the Cox proportional hazards model. Results: Our findings indicated a significantly decreased percentage of CD3+, and CD8+ cells, a significantly increased proportion of $CD4^+$, $CD19^+$, $CD44^+$, $CD25^+$, NK cells, and an increased $CD4^+/CD8^+$ ratio in GC patients as compared with healthy controls (all P < 0.05). Alteration of lymphocyte subsets was positively correlated with sex, age, smoking, tumor stage and distant metastasis of GC patients (all P<0.05). Follow-up analysis indicated significantly higher DFS for patients with high circulating $CD19^+$ lymphocytes compared to those with low $CD19^+$ lymphocytes (P=0.037), with $CD19^+$ showing an important cutoff of $7.91{\pm}2.98%$ Conclusion: Circulating lymphocyte subsets in GC patients are significantly changed, and elevated CD19+ cells may predict a favorable survival.

키워드

참고문헌

  1. Abes R, Teillaud JL (2011). Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer Metastasis Rev, 30, 111-24. https://doi.org/10.1007/s10555-011-9282-3
  2. Aburatani H (2005). Discovery of a new biomarker for gastroenterological cancers. Gastroenterol, 16, 1-6.
  3. Babaei M, Pourfarzi F, Yazdanbod A, et al (2010). Gastric cancer in Ardabil, Iran--a review and update on cancer registry data. Asian Pac J Cancer Prev, 11, 595-9.
  4. Ben-Baruch A (2006). Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol, 16, 38-52. https://doi.org/10.1016/j.semcancer.2005.07.006
  5. Bertuccio P, Chatenoud L, Levi F, et al (2009). Recent patterns in gastric cancer: a global overview. Int J Cancer, 125, 666-73. https://doi.org/10.1002/ijc.24290
  6. Block MS, Markovic SN (2009). The tumor/immune interface: clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion. Am J Immunol, 5, 29-49. https://doi.org/10.3844/ajisp.2009.29.49
  7. Cao W, Yang W, Li H, et al (2011). Using detection of survivinexpressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer. J Surg Oncol, 103, 110-5. https://doi.org/10.1002/jso.21777
  8. Cho Y, Miyamoto M, Kato K, et al (2003). CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res, 63, 1555-9.
  9. Costache M, Neagu M, Petrescu A, et al (2010). Statistical correlations between peripheral blood lymphocyte subpopulations and tumor inflammatory infiltrate in stage I of skin melanoma. Rom J Morphol Embryol, 51, 693-9.
  10. Dai F, Liu L, Che G, et al (2010). The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer, 10, 220.
  11. Domschke C, Schuetz F, Ge Y, et al (2009). Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res, 69, 8420-8. https://doi.org/10.1158/0008-5472.CAN-09-1627
  12. Dozois EJ, Privitera A, Holubar SD, et al (2011). High sacrectomy for locally recurrent rectal cancer: Can long-term survival be achieved? J Surg Oncol, 103, 105-9. https://doi.org/10.1002/jso.21774
  13. Duncavage E, Goodgame B, Sezhiyan A, et al (2010). Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol, 5, 1755-63. https://doi.org/10.1097/JTO.0b013e3181f3909d
  14. Feng J, Wu YF, Xu HM, et al (2011). Prognostic significance of the metastatic lymph node ratio in T3 gastric cancer patients undergoing total gastrectomy. Asian Pac J Cancer Prev, 12, 3289-92.
  15. Ferguson TA, Choi J, Green DR (2011). Armed response: how dying cells influence T-cell functions. Immunol Rev, 241, 77-88. https://doi.org/10.1111/j.1600-065X.2011.01006.x
  16. Gross S, Walden P (2008). Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. Immunol Lett, 116, 7-14. https://doi.org/10.1016/j.imlet.2007.11.012
  17. Hamai A, Benlalam H, Meslin F, et al (2010). Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens, 75, 1-8. https://doi.org/10.1111/j.1399-0039.2009.01401.x
  18. Huang RY, Chen GG (2011). Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochim Biophys Acta, 1815, 158-69.
  19. Ishikawa H, Tsuyama N, Mahmoud MS, et al (2002). CD19 expression and growth inhibition of tumours in human multiple myeloma. Leuk Lymphoma, 43, 613-6. https://doi.org/10.1080/10428190290012146
  20. Jeong E, Lee JY (2011). Intrinsic and extrinsic regulation of innate immune receptors. Yonsei Med J, 52, 379-92. https://doi.org/10.3349/ymj.2011.52.3.379
  21. Jochems C, Schlom J (2011). Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood), 236, 567-79. https://doi.org/10.1258/ebm.2011.011007
  22. Kalnina I, Kurjane N, Kirilova E, et al (2010). Correlation of altered blood albumin characteristics and lymphocyte populations to tumor stage in gastrointestinal cancer patients. Cancer Biomark, 7, 91-9. https://doi.org/10.3233/CBM-2010-0151
  23. Keystone EC, Ware CF (2010). Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl, 85, 27-39. https://doi.org/10.3899/jrheum.091463
  24. Kim R, Emi M, Tanabe K, et al (2006). Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res, 66, 5527-36. https://doi.org/10.1158/0008-5472.CAN-05-4128
  25. Lee YY, Oh DK, Choi KS, et al (2011). The current status of gastric cancer screening in Korea: report on the National Cancer Screening Programme, 2009. Asian Pac J Cancer Prev, 12, 3495-500.
  26. Lindblad M, Rodríguez LA, Lagergren J (2005). Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control, 16, 285-94. https://doi.org/10.1007/s10552-004-3485-7
  27. Mahmoud MS, Fujii R, Ishikawa H, et al (1999). Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood, 94, 3551-8.
  28. Nakajima M, Kato H, Miyazaki T, et al (2009). Tumor immune systems in esophageal cancer with special reference to heat-shock protein 70 and humoral immunity. Anticancer Res, 29, 1595-606.
  29. Nguyen J, Ivan D, Esmaeli B (2008). Conjunctival squamous cell carcinoma in the anophthalmic socket. Ophthal Plast Reconstr Surg, 24, 98-101. https://doi.org/10.1097/IOP.0b013e31816381fa
  30. Nozoe T, Maehara Y, Sugimachi K (2005). Preoperative sorting of circulating T lymphocytes in patients with esophageal squamous cell carcinoma: its prognostic significance. World J Gastroenterol, 11, 6689-93. https://doi.org/10.3748/wjg.v11.i42.6689
  31. Pawelek JM, Chakraborty AK (2008). The cancer cell--leukocyte fusion theory of metastasis. Adv Cancer Res, 101, 397-444. https://doi.org/10.1016/S0065-230X(08)00410-7
  32. Pisanu A, Montisci A, Piu S, et al (2007). Curative surgery for gastric cancer in the elderly: treatment decisions, surgical morbidity, mortality, prognosis and quality of life. Tumori, 93, 478-84. https://doi.org/10.1177/030089160709300512
  33. Powell AE, Anderson EC, Davies PS, et al (2011). Fusion between Intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. Cancer Res, 71, 1497-505. https://doi.org/10.1158/0008-5472.CAN-10-3223
  34. Qualls JE, Murray PJ (2011). Tumor macrophages protective and pathogenic roles in cancer development. Curr Top Dev Biol, 94, 309-28. https://doi.org/10.1016/B978-0-12-380916-2.00010-3
  35. Rey-Ferro M, Castaño R, Orozco O, et al (1997). Nutritional and immunologic evaluation of patients with gastric cancer before and after surgery. Nutrition, 13, 878-81. https://doi.org/10.1016/S0899-9007(97)00269-4
  36. Sabel MS (2009). Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology, 58, 1-11. https://doi.org/10.1016/j.cryobiol.2008.10.126
  37. Sagaert X, Van Cutsem E, De Hertogh G, et al (2010). Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol, 7, 336-46. https://doi.org/10.1038/nrgastro.2010.58
  38. Saif MW, Makrilia N, Zalonis A, et al (2010). Gastric cancer in the elderly: an overview. Eur J Surg Oncol, 36, 709-17. https://doi.org/10.1016/j.ejso.2010.05.023
  39. Sato N, Hirohashi Y, Tsukahara T, et al (2009). Molecular pathological approaches to human tumor immunology. Pathol Int, 59, 205-17. https://doi.org/10.1111/j.1440-1827.2009.02353.x
  40. Saurer L, Mueller C (2009). T cell-mediated immunoregulation in the gastrointestinal tract. Allergy, 64, 505-19. https://doi.org/10.1111/j.1398-9995.2009.01965.x
  41. Schmidt M, Böhm D, von Törne C, et al (2008). The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res, 68, 5405-13. https://doi.org/10.1158/0008-5472.CAN-07-5206
  42. Schreiber RD, Old LJ, Smyth MJ (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 331, 1565-70. https://doi.org/10.1126/science.1203486
  43. Shimada H, Takiguchi N, Kainuma O, et al (2010). High preoperative neutrophil- lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer, 13, 170-6. https://doi.org/10.1007/s10120-010-0554-3
  44. Smyth MJ, Cretney E, Kershaw MH, et al (2004). Cytokines in cancer immunity and immunotherapy. Immunol Rev, 202, 275-93. https://doi.org/10.1111/j.0105-2896.2004.00199.x
  45. Sobin LH, Gospodarowicz MK, Wittekind Ch. Eds (2009). TNM Classification of Malignant Tumors, 7th ed. Wiley-Blackwell, Oxford. 310 pages. ISBN 978-1 -4443-3241-4.
  46. Sweetenham JW, Goldman B, LeBlanc ML, et al (2010). Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol, 21, 1196-202. https://doi.org/10.1093/annonc/mdp460
  47. Tan HT, Low J, Lim SG, et al (2009). Serum autoantibodies as biomarkers for early cancer detection. FEBS J, 276, 6880-904. https://doi.org/10.1111/j.1742-4658.2009.07396.x
  48. Tramacere I, La Vecchia C, Negri E (2011). Tobacco smoking and esophageal and gastric cardia adenocarcinoma: a metaanalysis. Epidemiology, 22, 344-9. https://doi.org/10.1097/EDE.0b013e31821092cd
  49. Wang YX, Ruan CP, Li L, et al (1999). Clinical significance of changes of perioperative T cell and expression of its activatedantigen in colorectal cancer patients. World J Gastroenterol, 5, 181-2. https://doi.org/10.3748/wjg.v5.i2.181
  50. Wu HL, Tian Q, Peng CW, et al (2011). Multivariate survival and outcome analysis of 154 patients with gastric cancer at a single Chinese institution. Asian Pac J Cancer Prev, 12, 3341-5.
  51. Zhang N, Wen D, Shan B, et al (2011). Clustering and geographic variation of upper gastrointestinal cancers in a high-risk region of esophageal cancer in northern China. Asian Pac J Cancer Prev, 12, 193-8.

피인용 문헌

  1. Prognostic Value of Preoperative Inflammation-Based Prognostic Scores on Hospital Mortality after Gastric Cancer Surgery vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7909